Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
- PMID: 24167693
- PMCID: PMC3805432
- DOI: 10.1177/2045125312474019
Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
Abstract
Background: Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.
Methods: We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.
Results: Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse, hospitalization and suicide. Factors positively related to adherence were a good therapeutic relationship with physician and perception of benefits of medication. The most frequently reported driver and consequence were lack of insight and greater risk of hospitalization respectively.
Conclusions: Improving adherence in schizophrenia may have a considerable positive impact on patients and society. This can be achieved by focusing on the identified multitude of factors driving nonadherence.
Keywords: adherence; antipsychotics; nonadherence; schizophrenia; systematic review.
Conflict of interest statement
Figures
Similar articles
-
Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.Curr Med Res Opin. 2007 Oct;23(10):2305-12. doi: 10.1185/030079907X226050. Curr Med Res Opin. 2007. PMID: 17697454 Review.
-
Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia.Patient Prefer Adherence. 2013 Apr 4;7:275-84. doi: 10.2147/PPA.S41609. Print 2013. Patient Prefer Adherence. 2013. PMID: 23589681 Free PMC article.
-
Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.J Clin Psychiatry. 2002 Oct;63(10):892-909. doi: 10.4088/jcp.v63n1007. J Clin Psychiatry. 2002. PMID: 12416599 Review.
-
Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics.Psychiatr Serv. 2010 Dec;61(12):1239-47. doi: 10.1176/ps.2010.61.12.1239. Psychiatr Serv. 2010. PMID: 21123409
-
Approaches to improve adherence to pharmacotherapy in patients with schizophrenia.Patient Prefer Adherence. 2014 May 14;8:701-14. doi: 10.2147/PPA.S59371. eCollection 2014. Patient Prefer Adherence. 2014. PMID: 24868149 Free PMC article. Review.
Cited by
-
Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia.PLoS One. 2015 Mar 27;10(3):e0120560. doi: 10.1371/journal.pone.0120560. eCollection 2015. PLoS One. 2015. PMID: 25816353 Free PMC article.
-
The effect of the COVID-19 pandemic on health behavior and psychopathology in patients with psychotic disorders.Psychiatry Res. 2022 Nov;317:114845. doi: 10.1016/j.psychres.2022.114845. Epub 2022 Sep 13. Psychiatry Res. 2022. PMID: 36155276 Free PMC article.
-
The psychosis analysis in real-world on a cohort of large-scale patients with schizophrenia.BMC Med Inform Decis Mak. 2020 Jul 9;20(Suppl 3):132. doi: 10.1186/s12911-020-1125-0. BMC Med Inform Decis Mak. 2020. PMID: 32646484 Free PMC article.
-
Current Status of Therapeutic Drug Monitoring in Mental Health Treatment: A Review.Pharmaceutics. 2022 Dec 1;14(12):2674. doi: 10.3390/pharmaceutics14122674. Pharmaceutics. 2022. PMID: 36559168 Free PMC article. Review.
-
Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia.Schizophr Res Treatment. 2021 Nov 25;2021:8403986. doi: 10.1155/2021/8403986. eCollection 2021. Schizophr Res Treatment. 2021. PMID: 34868682 Free PMC article.
References
-
- Acosta F., Bosch E., Sarmiento G., Juanes N., Caballero-Hidalgo A., Mayans T. (2009) Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables. Schizophr Res 107: 213–217 - PubMed
-
- Ahn J., McCombs J., Jung C., Croudace T., McDonnell D., Ascher-Svanum H., et al. (2008) Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health 11: 48–56 - PubMed
-
- American Psychiatric Association (2006) Evidence-Based Treatments for Schizophrenia: Information for families and Other Supporters. Arlington, VA: American Psychiatric Association
-
- Ascher-Svanum H. (2006) A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry 67: 1114–1123 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources